Hypromellose

證據等級: L5

預測適應症: 10 個

Hypromellose: From Pharmaceutical Excipient to Hepatic Veno-Occlusive Disease-Immunodeficiency Syndrome

One-Sentence Summary

Hypromellose (hydroxypropyl methylcellulose, HPMC) is an inert semi-synthetic polymer with no established pharmacological therapeutic indication — it functions primarily as an excipient in pharmaceutical formulations (tablet coatings, ophthalmic lubricants, suspending agents). The TxGNN model predicts it may be effective for hepatic veno-occlusive disease-immunodeficiency syndrome with a prediction score of 98.30%, however no supporting clinical trials or published literature currently exist for this direction. Given the complete absence of a plausible mechanism of action and zero clinical evidence, this prediction is assessed as a likely model artefact rather than a genuine therapeutic opportunity.

Quick Overview

Item	Content
Original Indication	No established therapeutic indication (used as pharmaceutical excipient)
Predicted New Indication	Hepatic veno-occlusive disease-immunodeficiency syndrome
TxGNN Prediction Score	98.30%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for Hypromellose, as it is not classified as a pharmacologically active substance. Hypromellose is a semi-synthetic inert polymer derived from cellulose, used across pharmaceutical manufacturing as a film-coating agent for tablets (controlled-release formulations), a viscosity-modifying and lubricating agent in ophthalmic drops (artificial tears), and a suspending agent in oral liquid preparations. Its effects are entirely physical and physicochemical — film-forming, mucoadhesive, viscosity-modifying — with no known receptor binding, enzymatic inhibition, or biochemical signalling activity.

Hepatic veno-occlusive disease-immunodeficiency syndrome (VODI syndrome) is a rare autosomal recessive primary immunodeficiency disorder associated with mutations in genes such as VPS13B and WIPF1. The pathophysiology centres on defective immune signalling and hepatic sinusoidal endothelial injury, leading to progressive veno-occlusive disease and combined immunodeficiency. Effective pharmacological intervention in this condition requires agents capable of modulating immune cell development, endothelial protection, or fibrinolytic activation — none of which are properties attributable to an inert polymer excipient.

There is no established or plausible mechanistic link between Hypromellose and any of the predicted indications. The uniformly high TxGNN scores across all five top-ranked rare diseases most likely reflect a knowledge graph artefact: Hypromellose’s ubiquitous co-occurrence with thousands of active drugs in formulation data may have artificially inflated its graph connectivity, producing spurious high-confidence predictions unrelated to pharmacological activity. This interpretation is strongly supported by the complete absence of any supporting clinical trials or literature across all queried indications.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Hypromellose is an inert pharmaceutical excipient with no known pharmacological activity; all five unique top-ranked TxGNN predictions involve rare genetic diseases for which no mechanistic connection to Hypromellose exists, and zero clinical or preclinical supporting evidence was identified across all evidence sources queried.

To proceed, the following is needed:

Pipeline audit: Verify whether Hypromellose was correctly classified in the TxGNN input pipeline — known excipients and inactive ingredients should be excluded from repurposing candidate generation to prevent model artefacts
Knowledge graph review: Investigate whether Hypromellose’s high graph connectivity stems from co-formulation co-occurrence rather than pharmacological relationships, and apply appropriate edge filtering
Expert adjudication: If any downstream investigation is warranted, obtain an independent pharmacology expert assessment of whether HPMC can exert any direct biological activity at physiologically relevant concentrations
No further evidence collection is recommended at this stage for any of the predicted indications, as the foundational premise (pharmacological activity) has not been established
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.